The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell Metabolism

Volumn 26, Issue 2, 2017, Pages 343-352.e2

  Frias, Juan Pablo ^a   Bastyr, Edward J ^b   Vignati, Louis ^c   Tschöp, Matthias H ^d,e,f   Schmitt, Christophe ^g   Owen, Klara ^h   Christensen, Rune Haubo ^h   DiMarchi, Richard D ⁱ  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Former scientific advisor to MB2 LLC   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h NOVO NORDISK A S   (Denmark)

ⁱ NOVO NORDISK INC   (United States)

Author keywords

dual GIP GLP 1 agonist; GIP; GLP 1; metabolic disease; pharmacodynamics; safety; type 2 diabetes

Indexed keywords

ANTIBODY; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; NNC 0090 2746; PLACEBO; UNCLASSIFIED DRUG; CHOLESTEROL; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LEPTIN; LIRAGLUTIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; AGONISTS; BLOOD; CLINICAL TRIAL;

ADULT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS; LEPTIN; LIRAGLUTIDE; MALE; MIDDLE AGED;

EID: 85026313744     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.07.011     Document Type: Article

References (47)

1. Aaboe, K., Akram, S., Deacon, C.F., Holst, J.J., Madsbad, S., Krarup, T., Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes Obes. Metab. 17 (2015), 74–81.
2. Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007), 2131–2157.
3. Campbell, J.E., Drucker, D.J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17 (2013), 819–837.
4. Campbell, J.E., Ussher, J.R., Mulvihill, E.E., Kolic, J., Baggio, L.L., Cao, X., Liu, Y., Lamont, B.J., Morii, T., Streutker, C.J., et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat. Med. 22 (2016), 84–90.
5. Chia, C.W., Carlson, O.D., Kim, W., Shin, Y.K., Charles, C.P., Kim, H.S., Melvin, D.L., Egan, J.M., Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58 (2009), 1342–1349.
6. Davies, M.J., Bergenstal, R., Bode, B., Kushner, R.F., Lewin, A., Skjøth, T.V., Andreasen, A.H., Jensen, C.B., DeFronzo, R.A., NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
7. Dungan, K.M., Povedano, S.T., Forst, T., González, J.G., Atisso, C., Sealls, W., Fahrbach, J.L., Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384 (2014), 1349–1357.
8. Dupre, J., Ross, S.A., Watson, D., Brown, J.C., Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37 (1973), 826–828.
9. Finan, B., Ma, T., Ottaway, N., Müller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5, 2013, 209ra151.
10. Fineman, M.S., Mace, K.F., Diamant, M., Darsow, T., Cirincione, B.B., Booker Porter, T.K., Kinninger, L.A., Trautmann, M.E., Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes. Metab. 14 (2012), 546–554.
11. Gault, V.A., O'Harte, F.P., Harriott, P., Flatt, P.R., Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 290 (2002), 1420–1426.
12. Gault, V.A., Irwin, N., Green, B.D., McCluskey, J.T., Greer, B., Bailey, C.J., Harriott, P., O'harte, F.P., Flatt, P.R., Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54 (2005), 2436–2446.
13. Gutniak, M., Orskov, C., Holst, J.J., Ahrén, B., Efendic, S., Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326 (1992), 1316–1322.
14. Hermansen, K., Bækdal, T.A., Düring, M., Pietraszek, A., Mortensen, L.S., Jørgensen, H., Flint, A., Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes. Metab. 15 (2013), 1040–1048.
15. Højberg, P.V., Vilsbøll, T., Rabøl, R., Knop, F.K., Bache, M., Krarup, T., Holst, J.J., Madsbad, S., Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52 (2009), 199–207.
16. Irwin, N., Gault, V.A., Green, B.D., Greer, B., McCluskey, J.T., Harriott, P., O'Harte, F.P., Flatt, P.R., Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol. Chem. 385 (2004), 845–852.
17. Klonoff, D.C., Buse, J.B., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., Wintle, M.E., Maggs, D.G., Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24 (2008), 275–286.
18. Knop, F.K., Vilsbøll, T., Højberg, P.V., Larsen, S., Madsbad, S., Holst, J.J., Krarup, T., The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul. Pept. 144 (2007), 123–130.
19. Knop, F.K., Vilsbøll, T., Højberg, P.V., Larsen, S., Madsbad, S., Vølund, A., Holst, J.J., Krarup, T., Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes 56 (2007), 1951–1959.
20. Kreymann, B., Williams, G., Ghatei, M.A., Bloom, S.R., Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987), 1300–1304.
21. le Roux, C.W., Astrup, A., Fujioka, K., Greenway, F., Lau, D.C.W., Van Gaal, L., Ortiz, R.V., Wilding, J.P.H., Skjøth, T.V., Manning, L.S., Pi-Sunyer, X., SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389 (2017), 1399–1409.
22. Lorenz, M., Evers, A., Wagner, M., Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg. Med. Chem. Lett. 23 (2013), 4011–4018.
23. Maffei, M., Halaas, J., Ravussin, E., Pratley, R.E., Lee, G.H., Zhang, Y., Fei, H., Kim, S., Lallone, R., Ranganathan, S., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1 (1995), 1155–1161.
24. McClean, P.L., Irwin, N., Cassidy, R.S., Holst, J.J., Gault, V.A., Flatt, P.R., GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293 (2007), E1746–E1755.
25. McIntyre, N., Holdsworth, C.D., Turner, D.S., New interpretation of oral glucose tolerance. Lancet 2 (1964), 20–21.
26. Mentis, N., Vardarli, I., Köthe, L.D., Holst, J.J., Deacon, C.F., Theodorakis, M., Meier, J.J., Nauck, M.A., GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60 (2011), 1270–1276.
27. Milicevic, Z., Anglin, G., Harper, K., Konrad, R.J., Skrivanek, Z., Glaesner, W., Karanikas, C.A., Mace, K., Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide. Diabetes Obes. Metab. 18 (2016), 533–536.
28. Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8 (2002), 738–742.
29. Møller, C.L., Vistisen, D., Færch, K., Johansen, N.B., Witte, D.R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Jørgensen, M.E., et al. Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study. J. Clin. Endocrinol. Metab. 101 (2016), 485–493.
30. Nauck, M.A., Meier, J.J., The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 4 (2016), 525–536.
31. Nauck, M.A., Homberger, E., Siegel, E.G., Allen, R.C., Eaton, R.P., Ebert, R., Creutzfeldt, W., Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63 (1986), 492–498.
32. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993), 301–307.
33. Nauck, M.A., Wollschläger, D., Werner, J., Holst, J.J., Orskov, C., Creutzfeldt, W., Willms, B., Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39 (1996), 1546–1553.
34. Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H., Zdravkovic, M., Düring, M., Matthews, D.R., LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32 (2009), 84–90.
35. Nauck, M., Frid, A., Hermansen, K., Thomsen, A.B., During, M., Shah, N., Tankova, T., Mitha, I., Matthews, D.R., Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes. Metab. 15 (2013), 204–212.
36. Neff, L.M., Kushner, R.F., Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes Metab. Syndr. Obes. 3 (2010), 263–273.
37. Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E.C., Biryukov, S., Abbafati, C., Abera, S.F., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 766–781.
38. Plutzky, J., Garber, A., Falahati, A., Toft, A.D., Poulter, N.R., Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. Can. J. Diabetes 33 (2009), 209–210.
39. Portron, A., Jadidi, S., Sarkar, N., DiMarchi, R., Schmitt, C., Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual GIP/GLP-1 agonist (RG7697) after single subcutaneous administration in healthy subjects. Diabetes Obes. Metab., 2017, 10.1111/dom.13025.
40. Reusch, J., Stewart, M.W., Perkins, C.M., Cirkel, D.T., Ye, J., Perry, C.R., Reinhardt, R.R., Bode, B.W., Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes. Metab. 16 (2014), 1257–1264.
41. Rosenbaum, M., Nicolson, M., Hirsch, J., Murphy, E., Chu, F., Leibel, R.L., Effects of weight change on plasma leptin concentrations and energy expenditure. J. Clin. Endocrinol. Metab. 82 (1997), 3647–3654.
42. Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., DiMarchi, R., Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual GIP/GLP-1 agonist RG7697 in patients with type 2 diabetes mellitus. Diabetes Obes. Metab., 2017, 10.1111/dom.13024.
43. Tschöp, M.H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T.D., DiMarchi, R.D., Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 24 (2016), 51–62.
44. Vilsbøll, T., Krarup, T., Madsbad, S., Holst, J.J., Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45 (2002), 1111–1119.
45. World Health Organization (2016). Global Report on Diabetes. Available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf. Accessed July 4, 2017.
46. Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., Lakshmanan, M., Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 37 (2014), 2159–2167.
47. Xu, G., Kaneto, H., Laybutt, D.R., Duvivier-Kali, V.F., Trivedi, N., Suzuma, K., King, G.L., Weir, G.C., Bonner-Weir, S., Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56 (2007), 1551–1558.